LOUISE MUHOZI: Open Payments
NPI 1114305331 · KANSAS CITY, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,407 in 269 payments from 13 companies in 2025. Trend: 2023 $2,607 · 2024 $3,379 · 2025 $3,407
Food & beverage: $3,387Education: $20
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 29 | $433 |
| ABBVIE INC. | 37 | $398 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $392 |
| Otsuka America Pharmaceutical, Inc. | 26 | $346 |
| Alkermes, Inc. | 19 | $343 |
| Neurocrine BioSciences, Inc. | 20 | $341 |
| Vanda Pharmaceuticals Inc. | 41 | $298 |
| Janssen Pharmaceuticals, Inc | 11 | $256 |
| Axsome Therapeutics, Inc. | 17 | $225 |
| Teva Pharmaceuticals USA, Inc. | 19 | $180 |
Products named: COBENFY, VRAYLAR, CAPLYTA, INGREZZA, REXULTI, ARISTADA, INVEGA SUSTENNA, HETLIOZ.
Industry payments across KS — which companies pay providers there.
